Gene Therapy Trial at the Retina Foundation of the Southwest featured in The Dallas Morning News
Mason Two Crow, 22, first came to the Retina Foundation in 2003 with a diagnosis of X-linked retinoschisis, a rare genetic condition affecting the retina. Two years ago he came in for a follow-up appointment where he learned that he had the opportunity to be one of the very first to ever be enrolled in a gene therapy trial for his rare eye disease. Mason gives credit to the research scientists at the Retina Foundation for gifting him with the hope that a cure for X-linked retinoschisis may be on the horizon. Click here to read more of Mason’s incredible story on www.dallasnews.com.
Related Articles
Retina Foundation Helps Avery National Eye Institute Awards $949,804 for a 5-Year Study of RP Retina Foundation Has Eye on $1 Million Goal for Annual Visionary Luncheon Video Game Software Patented for Age-Related Macular Degeneration Research Who Are The Brothers In Toyota’s Super Bowl 2022 Commercial?